The Directorate General of Health Services has opened a discussion on the use of brand name extensions by pharmaceutical companies, aiming to address a long-standing concern regarding product differentiation and consumer awareness.
CDSCO Calls for Comments on Pharma Brand Name Extensions
On July 6, 2026, the Directorate General of Health Services (DGHS) under the Central Drugs Standard Control Organization (CDSCO) issued a notice inviting public comments on brand name extensions utilized by pharmaceutical companies. This notice follows a representation to the Drugs Consultative Committee that raised concerns about pharmaceutical companies selling different formulations under a single brand name yet using various extensions.
This announcement seeks to address a critical issue in pharmaceutical marketing, where brand name extensions may complicate consumer understanding and lead to confusion regarding product efficacy and safety. The ongoing lack of clarity regarding permissible brand name extensions raises important questions about marketing standards and regulatory compliance.
Experts, including Prashant and Dinesh Thakur, emphasize that scrutiny of brand extensions is crucial for safeguarding consumer interests and ensuring responsible marketing practices within the pharmaceutical sector. They argue that clearer regulations are necessary to enable consumers to make informed choices regarding medications.
For practitioners in regulatory compliance and pharmaceutical law, this development signifies an urgent need to reassess branding strategies. Lawyers must remain attuned to emerging guidelines and changing practices concerning pharmaceutical marketing and regulatory standards as this discourse unfolds.
Citations
- N/A
